GLP-1 cost without insurance looks impossibly high at first glance. Most people see a number well above $1,000 a month and assume that’s their only option. The reality in 2026 is more complicated, and more encouraging. Manufacturer cash-pay programs, a new oral option, and a fresh Medicare benefit have all changed what “without insurance” actually means for these medications.
This guide breaks down GLP-1 cost without insurance for Ozempic, Wegovy, and Zepbound specifically. It covers the cash-pay programs that bring the price down dramatically for eligible patients. If you’re comparing this against a surgical path, see our gastric sleeve cost by state guide for how that alternative compares.
This article is for general informational purposes only. It is not medical advice and does not replace a conversation with your prescribing physician or pharmacist. Figures and program details are 2026 estimates based on published manufacturer and pharmacy pricing, which change frequently. Confirm current pricing directly with NovoCare, LillyDirect, or your pharmacy before assuming any figure below still applies.
Quick Answer
At full list price, GLP-1 cost without insurance runs $968 to $1,640 per month, depending on the specific medication. Manufacturer cash-pay programs change that picture significantly. Oral Wegovy through NovoCare starts around $149 to $299/month, and Zepbound vials through LillyDirect run $299 to $449/month. Ozempic, by contrast, has no dedicated manufacturer cash-pay program. Uninsured patients typically pay closer to full list price unless they explore a compounded alternative.
Because these cash-pay programs exist outside standard insurance, checking them directly is worth doing even if you assume you can’t afford any GLP-1 medication.
GLP-1 Cost Without Insurance, by Medication
| Medication | List price (retail) | Cash-pay program price |
|---|---|---|
| Ozempic (semaglutide, injectable) | ~$968 – $1,000/month | No dedicated manufacturer cash program |
| Wegovy (semaglutide, injectable) | ~$1,349 – $1,640/month | Savings card can lower this, but only alongside insurance |
| Wegovy (semaglutide, oral pill, new in 2026) | N/A — cash-pay only | ~$149/month starter dose, rising to ~$299/month at maintenance dose |
| Zepbound (tirzepatide, pen) | ~$1,000 – $1,271/month | No dedicated pen cash program |
| Zepbound (tirzepatide, vials via LillyDirect) | N/A — cash-pay only | $299 – $449/month, depending on dose |
Ozempic and Wegovy are the same drug (semaglutide) from Novo Nordisk. Zepbound and Mounjaro are the same drug (tirzepatide) from Eli Lilly. The brand name mainly reflects which condition it’s approved and marketed for — diabetes versus weight management. Unlike weight loss surgery cost with insurance, which usually requires meeting BMI and documentation criteria, GLP-1 coverage rules work somewhat differently, as covered below.
Why Cash-Pay Programs Work Differently Than a Coupon
This is the detail that confuses a lot of patients. Manufacturer savings cards can bring a copay to $25/month. But they function as secondary coverage that works alongside commercial insurance — they don’t apply if you have no insurance at all. Cash-pay programs like NovoCare (for oral Wegovy) and LillyDirect (for Zepbound vials) work differently. They’re direct-to-patient sales programs designed specifically for patients paying entirely out of pocket, with no insurance involved.
Because of this distinction, an uninsured patient should look at NovoCare and LillyDirect specifically. The manufacturer’s standard savings card won’t apply without underlying insurance.
The New Medicare GLP-1 Bridge Program
As of July 1, 2026, Medicare added a GLP-1 Bridge Program. It covers Wegovy, Zepbound (KwikPen), and select other GLP-1s at roughly $50/month for eligible Part D enrollees. This is a meaningful shift: Medicare has historically excluded weight-loss medications entirely, only covering GLP-1s prescribed for type 2 diabetes. If you’re on Medicare and considering a GLP-1 for weight management, check your Part D plan’s current Bridge Program eligibility directly, since this benefit is new and still being rolled out.
Separately, the Inflation Reduction Act caps Part D out-of-pocket semaglutide costs at $2,000/year for diabetes-indicated use, starting in 2026. This is a different provision than the Bridge Program, and it only applies to the diabetes indication specifically.
Compounded GLP-1s: A Cheaper but Riskier Path
Compounded semaglutide and tirzepatide are versions prepared by compounding pharmacies rather than the brand manufacturer. They typically cost $99 to $269/month for semaglutide and $150 to $399/month for tirzepatide, well below both list price and most cash-pay programs.
However, FDA enforcement around compounded GLP-1s tightened in 2025, and sourcing quality varies significantly between compounding pharmacies. If you’re considering this route, verify that the specific pharmacy uses third-party testing and operates under proper regulatory oversight. This matters more here than with brand-name medication, where manufacturing standards are federally regulated and consistent.
Insurance With Prior Authorization: What to Expect
If you do have commercial insurance, coverage typically requires prior authorization rather than being automatic. A commonly cited example: Aetna’s clinical policy requires a BMI of 35+ and documentation of 6 or more months in a behavioral weight-management program before approving GLP-1 coverage for weight loss. When approved, commercial insurance with prior authorization commonly brings the monthly cost to $25 to $250, depending on your specific plan’s copay structure.
Ozempic tends to be the easiest to get approved. A type 2 diabetes diagnosis is a more established, less contested indication than weight management alone.
What’s Coming: A Price Cut on the Horizon
Novo Nordisk announced in February 2026 that it will cut Wegovy’s US list price to $675/month, roughly a 50% reduction, starting January 1, 2027. If your timeline allows some flexibility, factor this into your planning, since the current list-price gap may narrow significantly within the next year.
The FDA maintains current guidance and enforcement actions related to compounded GLP-1 medications, and the Centers for Medicare & Medicaid Services publishes official details on the Medicare GLP-1 Bridge Program and Part D coverage rules.
Questions to Ask Before You Choose a Path
- Does my insurance require prior authorization for a GLP-1, and what specific documentation do I need to qualify?
- Am I eligible for the Medicare GLP-1 Bridge Program if I’m on Medicare?
- Does NovoCare’s oral Wegovy or LillyDirect’s Zepbound vials fit my specific dose needs and prescription?
- If considering a compounded version, does this specific pharmacy provide third-party testing results?
- Should I wait for the announced 2027 price reduction, or does my situation call for starting treatment now?
Frequently Asked Questions
Is oral Wegovy the same medication as injectable Wegovy? Yes, both deliver semaglutide, just in different forms. The oral version launched in 2026 specifically to offer a lower-cost, cash-pay option through NovoCare, separate from the injectable’s standard retail pricing.
Why doesn’t Ozempic have a cash-pay program like Wegovy and Zepbound? Ozempic is primarily marketed and approved for type 2 diabetes. Wegovy and Zepbound are specifically approved and marketed for weight management, where manufacturers have built out dedicated direct-to-patient pricing programs to compete for cash-pay patients.
Is compounded semaglutide safe? Quality varies by pharmacy, and FDA oversight of compounded medications differs from oversight of FDA-approved brand-name drugs. If you consider this route, research the specific compounding pharmacy’s sourcing and testing practices carefully.
Will GLP-1 cost without insurance keep dropping? Recent trends suggest yes, at least directionally. Novo Nordisk’s announced 2027 price cut and the expansion of direct-to-patient cash-pay programs both point toward lower costs over time, though pricing in this market has changed quickly and can shift again.
Sources and figures referenced in this guide come from 2026 manufacturer, pharmacy, and CMS published pricing data. This article doesn’t recommend any specific medication, pharmacy, or program. Confirm current pricing and eligibility directly with NovoCare, LillyDirect, your insurer, or CMS, and consult your prescribing physician to determine which option fits your medical needs.